A three-arm, randomized, open-label, phase II study of everolimus in combination with exemestane versus everolimus alone versus capecitabine in the treatment of postmenupausal women with estrogen receptor postive, locally advanced, recurrent or metastatic breast cancer after recurrence or progression on prior letrozole or anastrozole.

drug protocol number
CRAD001Y2201
drug sponsor
Novartis
drug study
Everolimus + Exemestane VS. Everolimus VS. Capecitabine
drug trial site
KFSH & RC-R
drug status
Rejected
drug phase